Rhenman & Partners Asset Management Ab Phathom Pharmaceuticals, Inc. Transaction History

Rhenman & Partners Asset Management Ab

  • $1.2 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022
BUY
$11.55 - $20.06 $565,950 - $982,939
49,000 Added 26.31%
235,210 $3.2 Million
Q2 2021

Aug 13, 2021
BUY
$32.66 - $39.87 $366,118 - $446,942
11,210 Added 6.41%
186,210 $6.3 Million
Q4 2020

Jan 19, 2021
BUY
$33.22 - $50.26 $5.81 Million - $8.8 Million
175,000 New
175,000 $5.81 Million

Others Institutions Holding PHAT

# of Institutions
144
Shares Held
73.6M
Call Options Held
42.3K
Put Options Held
45.7K
View Full List

About Phathom Pharmaceuticals, Inc.

PHAT Quotes by TradingView
  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $292M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Rhenman & Partners Asset Management Ab Portfolio

Follow Rhenman & Partners Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email